| News

Evolva brings natural sugar blocker to market

21.01.2021

The biotech company Evolva is introducing L-arabinose to the market. This product is a natural sugar blocker and can be used both for healthy eating and as a reducing sugar in food processing.

Research and development in a laboratory of Evolva (img: Evolva)

Evolva, a biotech company headquartered in Reinach in the canton of Basel-Landschaft, has presented its new product L-arabinose, a natural sugar blocker. According to a press release, studies have demonstrated the effect of L-arabinose on adjusting to a healthy blood sugar level. The sugar blocker can also help with maintaining a healthy weight, for example by foregoing food and drink that contains a lot of sugar. L-arabinose is created by fermentation and is a good substitute for sugar in products such as yogurt, chocolate, soft drinks, ice cream, cereals, energy bars, and confectionary. The company’s press release states that its effect as a reducing sugar means that it can be used to create salty and savory chicken and beef flavors.

Oliver Walker, CEO of Evolva, is quoted as saying: “As people around the world continue to strive to live a healthier lifestyle, we are committed to helping our customers create healthier, more sustainable solutions. With this launch we are confirming our ability to deliver innovations that support human health and wellbeing.”

This new, natural sugar blocker is also of economic interest. Evolva has a current market volume of 250 million Swiss francs, and market growth of around 5 percent per year is anticipated. Evolva has revealed that marketing discussions are already underway with major clients.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Botanikind settles in Basel
Basel Area Business & Innovation, Innovation, Invest

Botanikind settles in Basel

The internationally active Swiss company Botanikind has settled in Basel and established Botanikind AG there. It provides natural ingredients for...

Read More
Kinarus secures capital commitment of 57 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Kinarus secures capital commitment of 57 million Swiss francs

The biopharmaceutical company Kinarus has signed a capital commitment of up to 57 million Swiss francs with the investment group...

Read More
Biotech startups from the Basel Area confirm leading position
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Biotech startups from the Basel Area confirm leading position

As part of the Top 100 Swiss Startup Awards 2021, the most promising startups in Switzerland are honored. These also...

Read More
T3 Pharma wins Swiss Economic Award
Basel Area Business & Innovation, Innovation, Invest

T3 Pharma wins Swiss Economic Award

T3 Pharma has won the Swiss Economic Award 2021. Switzerland’s most prestigious young entrepreneur prize is awarded by the Swiss...

Read More
Worg selects Basel Area for European headquarters
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Worg selects Basel Area for European headquarters

Worg Pharmaceuticals has opted to establish its European headquarters at the site Allschwil of the Switzerland Innovation Park Basel Area....

Read More
ten23 health settles in Basel
Basel Area Business & Innovation, Innovation, Invest

ten23 health settles in Basel

The life sciences cluster Rosental Mitte located in Basel is home to a new, globally active company called ten23 health....

Read More
1 2 3 48

Do you have a question? We'd like to hear from you.